Bright Green Announces Decision to Complete Alterola Biotech Acquisition

Bright Green to acquire remaining 75% of Alterola common stock

Agreements and completion will be subject to customary conditions and regulatory and stockholder approvals

Alterola will support Bright Green's activities to manufacture and distribute federally compliant, pharmaceutical-grade cannabis and derivatives

GRANTS, N.M., April 04, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that it will move forward with its previously announced strategic arrangement and confirms its intention to exercise the call option on the total acquisition of the remaining issued and outstanding common stock of Alterola Biotech (OTC:ABTI), a U.K.-based pharmaceutical company focused on developing cannabinoid and cannabinoid-like medicines and products.

By exercising its option to purchase Alterola's remaining issued and outstanding common stock over the coming months, Bright Green will complete the acquisition using Bright Green common stock.

"Today's announcement is the culmination of discussions and confirmation of our intention to acquire Alterola," said Bright Green's Chief Executive Officer, Seamus McAuley. "Alterola's deep sectoral expertise and pharmaceutical assets will help us more efficiently scale our operations and harness the therapeutic benefits of the Alterola Cannabinoid and Cannabinoid-like medicines, as well as bring a clear path to revenue in 2023."

"Combining Bright Green and Alterola is a very exciting prospect," said Alterola Executive Chairman, Tim Rogers. "Our organizations share a common mission to harness the therapeutic potential of medical cannabis and cannabis-based medicines. We look forward to blending our intellectual property programs into Bright Green – particularly at this important period in the company's trajectory – and accelerating the pharmaceutical development and commercialization of these important therapies. Bright Green's facilities in New Mexico, in combination with our Memorandum of Agreement from the U.S. Drug Enforcement Administration, brings a huge asset to bear on the Alterola pipeline and brings us closer to delivering the therapeutic benefits of our drug candidates."

About Bright Green

Bright Green is one of the very few companies selected by the US government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Our conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us.

About Alterola Biotech

Alterola Biotech Inc. is a UK based pharmaceutical company developing cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs) and targeting European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products.

Cautionary Note Regarding Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") on March 29, 2022 and declared effective May 13, 2022, and in the Company's Quarterly Report on Form 10-Q/A filed with the SEC on August 19, 2022, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the Company's results is included in the Company's SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov.

Bright Green Media Contact

[email protected]

Bright Green Investor Relations Contact

[email protected]

Alterola Investor Relations Contact

[email protected]